Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Regulatory Affairs Patient Care Phase 2 Trials Oncology Patient Outcomes GLP-1 Medications FDA Regulations Regulatory Approval Novo Nordisk Fast Track Designation by FDA Trial Outcomes Oncology Treatments Eli Lilly Phase 3 Trials

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

A twice-daily regimen hit key efficacy measures prompting MapLight to seek FDA input on a registrational trial.

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion